Form 4: ARS Pharmaceuticals Director Acquires Stock Options

Peter A. Thompson, a director of ARS Pharmaceuticals, acquired stock options for 40,000 shares of common stock on June 20, 2024.

Summary

• Peter A. Thompson, a director at ARS Pharmaceuticals, acquired stock options to purchase 40,000 shares of the company's common stock.
• The transaction occurred on June 20, 2024, with an exercise price of $7.73 per share.
• The options vest fully on the earlier of June 20, 2025, or the date of the Issuer's 2025 annual meeting of stockholders.
• Thompson is obligated to transfer any securities issued under the stock options, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock option grant. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors and officers. This allows investors to track ownership changes and potential alignment of interests between management and shareholders.

Stakeholder Impact

• The acquisition of stock options by a director could signal confidence in the company's future prospects, potentially impacting shareholder sentiment positively.
• The vesting schedule aligns the director's interests with the company's performance over the next year.

Key Dates